alexa A Systematic Approach on Highly Potent Pathogens | Open Access Journals
ISSN: 2155-9821
Journal of Bioprocessing & Biotechniques
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Systematic Approach on Highly Potent Pathogens

Vishal Bundele*
Executive Engineer, Process at Elomatic Pharmalab Consulting & Engineering Pvt Ltd in Mumbai, India
Corresponding Author : Vishal Bundele
Executive Engineer
Process at Elomatic Pharmalab Consulting & Engineering Pvt Ltd in Mumbai, India
Tel: 91-9324036715
E-mail: [email protected]
Received July 24, 2014; Accepted July 29, 2014; Published August 04, 2014
Citation: Bundele V (2014) A Systematic Approach on Highly Potent Pathogens. J Bioprocess Biotech 4: 172 doi:10.4172/2155-9821.1000172
Copyright: © 2014 Bundele V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioprocessing & Biotechniques

Abstract

The need for the contained handling and processing of pharmaceutical materials and pathogens is on the rise due to the increased focus on health and safety and the growing interest in the development of High Potency Active Pharmaceutical Ingredients (HPAPIs). A wide range of containment equipment is available on the market to meet the processing and operational needs of development and manufacturing. Selecting suitable equipment, however, requires an in-depth understanding of containment aspects in order to avoid operational hazards and large capital investments resulting from an ‘oversizing’ approach

Introduction
The need for the contained handling and processing of pharmaceutical materials and pathogens is on the rise due to the increased focus on health and safety and the growing interest in the development of High Potency Active Pharmaceutical Ingredients (HPAPIs). A wide range of containment equipment is available on the market to meet the processing and operational needs of development and manufacturing. Selecting suitable equipment, however, requires an in-depth understanding of containment aspects in order to avoid operational hazards and large capital investments resulting from an ‘oversizing’ approach.
In containment equipment selection the focus is on preventing the personnel from being exposed to hazardous substances. The equipment can-not, however, fully prevents exposure. It is thus important to ensure that expo-sure through containment equipment over the operational course of time is less than the product/pharmaceutical material exposure limit. The selection of suitable containment equipment requires a thorough understanding of product and equipment related exposure limits.
Product Exposure Limit
The product exposure limit is defined in terms of the occupational expo-sure limit (OEL), which is calculated based on the No Observable Effect Level (NOEL). The NOEL value is obtained by testing the pharmaceutical material on the species with daily dos-age increases until the observable effect or reaction can be seen. The OEL can thus be calculated with the following formula:
V: Volume of breath per human per day (8–10 m3;/8-hour of shift)
SF1 and SF2: Safety factors for establishing a correlation between species and individuals if data for the humans is not available
Equipment Exposure Limit
The exposure limit of the equipment can only be determined through air sampling procedures and then analysing the collected airborne particle samples. This amount is then divided by the volume of air sampled and the sampling time to give the Time Weighted Average (TWA) values of the exposure limit.
The TWA for evaluating pharmaceutical material is defined for 15 min as the Short Term Time Weighted Average (STTWA) and for 8 hours as the Long Term Time Weighted Average (LTTWA) (Figure 1).
Correlation Between OEL and TWA
Containment equipment needs be de-signed or selected in order to achieve LTTWA < OEL. The LTTWA can also be obtained from the STTWA considering the actual exposure time in the operational shifts. For example, the general industrial shift duration is 8 hours and the STTWA values for an exposure time of 15 min are available, then LTTWA based on STTWA can be calculated as follows.
TWA: Time Weighted Average
LTTWA: Long Term TWA
STTWA: Short Term TWA
NoC: Number of cycles
DF: Dilution Factor
A factor of 32 is used as there are four cycles of 15 minutes in an hour and the dilution factors is available data for STTWA for a 100% concentration of pharmaceutical material.
The containment equipment should as such be selected so that LTTWA is lower than the product-specific OEL.
Equipment Evaluation
The selected equipment can be evaluated by considering a worst case scenario where LTTWA = OEL and then calculating the STTWArequired from the aforementioned formula as follows:
TWA: Time Weighted Average
STTWA: Short Term TWA
NoC: Number of cycles
DF: Dilution Factor
The containment equipment can then be physically tested through appro-priate methods to evaluate the following:
STTWA < STTWArequired
Methods of Isolation and Selection
As indicated earlier the OEL of pharmaceutical materials is the basis for the selection of the containment level required for processing the material. Thus, as the OEL limit shows a tendency towards lower values a more sophisticated level of isolation is required to carry out the safe processing of the pharmaceutical material.
The different types of isolation methods available are provided in Table 1. The appropriate isolation method is selected based on the criticality of the material handled or processed. In essence it is based on the OEL, the physical characteristics of the materials, the quantity handled and the duration of pharmaceutical material processing (Figure 2).
Proper Selection and Meeting Owner’s Requirements
HPAPI is currently one of the fastest growing segments in the pharmaceutical industry, with a growth rate of 8 to 10 per cent. This high growth rate is attributed to their application in the formulation of high potent drugs used to combat some of the severest dis-eases. The market opportunities and treatment capabilities have resulted in the increased interest shown by pharmaceutical companies in investing in the development and manufacturing of HPAPI.
Handling these materials, however, requires sophisticated isolation methods, which demands an understanding of the basic concepts of containment engineering. This understanding assists in the proper selection of the suitable isolation method thereby meeting the operational and financial requirements of the owner.

Tables and Figures at a glance

Table icon
Table 1


Figures at a glance

Figure Figure
Figure 1 Figure 2
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 17th Euro Biotechnology Congress
    September 25-27, 2017 Berlin, Germany
  • 2nd World Biotechnology Congress
    December 04-06, 2017 Sao Paulo, Brazil

Article Usage

  • Total views: 11469
  • [From(publication date):
    November-2014 - Sep 19, 2017]
  • Breakdown by view type
  • HTML page views : 7710
  • PDF downloads :3759
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords